Small Cell Lung Cancer Pipeline Insight 2025' report provides comprehensive global coverage of pipeline NSCLC therapies in ...

Ancestry-based differences in frequencies of biomarkers that drive patient selection for treatment with precision oncology ...

在当今学术界，数据的准确性和研究结果的真实性是不可或缺的。这是谁都知晓的常识。然而，近日澳门科技大学的一篇论文引发了广泛关注和质疑，令人不得不思考：我们的科研是否存在隐忧？ 该论文题为"Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Facto ...

Technoderma Medicines has completed its phase 2a trial of TDM-180935 for the treatment of atopic dermatitis, demonstrating ...

IDRx’s lead candidate IDRX-42 is being investigated in a Phase I/IIb trial in patients with advanced gastrointestinal stromal ...

In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal ...

H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Cogent Biosciences (COGT) to $14 from $17 and keeps a Buy rating on the ...

The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.

Blueprint Medicines is cutting funding to its clinical-stage CDK2 inhibitor even as the Ayvakit-maker pushes forward with ...

Elevations in biomarkers such as uterine artery pulsatility index and placental growth factor throughout pregnancy indicate ...